Genmab (GMAB)
(Delayed Data from NSDQ)
$27.46 USD
-0.06 (-0.22%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $27.47 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Industry / Sector Report
Industry : Medical - Biomedical and Genetics
Zacks Industry Rank
Top 35% (86 out of 249)Zacks Sector Rank
Top 31% (5 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 2.28 | 1.37 | 9.99 |
Current Quarter Estimate | 0.30 | 2.89 | 61.00 |
Year Ago Quarter Estimate | 0.47 | -4.83 | 54.84 |
Next Quarter Estimate | 0.30 | 3.94 | 63.00 |
Next Year Estimate | 1.45 | 25.11 | 275.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | 2.54 | 17.50 | 15.67 |
Next Year | 19.83 | 9.40 | 11.34 |
Last 5 Years | NA | 0.90 | 8.10 |
Next 5 Years | 26.10 | 21.70 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | 22.74 | -7.39 |
Price/Book (MRQ) | 4.07 | 2.05 |
Price/Cash Flow (MRFY) | 22.20 | 17.40 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | 29.06% | -147.72% |
Return on Equity (TTM) | 17.48% | -60.91% |
Debt to Equity (MRQ) | 0.00 | 0.00 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.